The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-09-13
DOI
10.3389/fimmu.2022.964442
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation
- (2022) Shi-Suo Du et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
- (2022) Jonathan D Schoenfeld et al. LANCET ONCOLOGY
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
- (2022) Ming Yi et al. Molecular Cancer
- Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
- (2022) Chaoyuan Kuang et al. Clinical Epigenetics
- Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
- (2022) Chunhui Jin et al. Journal of Comparative Effectiveness Research
- Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
- (2022) Takashi Seto et al. Journal for ImmunoTherapy of Cancer
- Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men
- (2022) Paul Katongole et al. Oncology and Therapy
- Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial
- (2022) Jwa Hoon Kim et al. BMC CANCER
- Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis
- (2022) Hao Zuo et al. CANCER GENE THERAPY
- Classification of PD‐L1 expression in various cancers and macrophages based on immunohistocytological analysis
- (2022) Yoichi Saito et al. CANCER SCIENCE
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- (2022) Jason J Luke et al. LANCET
- Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2022) Carlotta Antoniotti et al. LANCET ONCOLOGY
- Autophagy in cancer cell remodeling and quality control
- (2022) Grace A. Hernandez et al. MOLECULAR CELL
- Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
- (2022) Jianqiong Yin et al. Frontiers in Immunology
- Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
- (2022) Xiaozhen Zhang et al. Journal for ImmunoTherapy of Cancer
- PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
- (2022) Hanqun Zhang et al. Frontiers in Oncology
- Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
- (2022) Weiran Xu et al. Frontiers in Oncology
- Role and regulation of autophagy in cancer
- (2022) Ravichandran Rakesh et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
- (2021) Federica Costa et al. Cancers
- Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
- (2021) Johanna Veldman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
- (2021) Cunte Chen et al. Frontiers in Pharmacology
- A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer
- (2021) Dae Won Kim et al. BRITISH JOURNAL OF CANCER
- Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
- (2021) Dan Liu et al. EUROPEAN JOURNAL OF CANCER
- Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma
- (2021) Tudor Mocan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
- (2021) Alison P. Klein Nature Reviews Gastroenterology & Hepatology
- An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation
- (2021) Zhijie Cao et al. Science Advances
- Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
- (2021) Romain Banchereau et al. Journal for ImmunoTherapy of Cancer
- Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
- (2021) Brendan D Curti et al. Journal for ImmunoTherapy of Cancer
- Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
- (2021) Julia Peña-Asensio et al. Cancers
- Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia
- (2021) Ramin Radpour et al. Frontiers in Oncology
- Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade
- (2021) Kun Tu et al. ACS Applied Materials & Interfaces
- High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer
- (2021) Katharina Möller et al. ACTA ONCOLOGICA
- Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials
- (2021) Wu Ye et al. BMC CANCER
- CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer
- (2021) Dirk De Ruysscher et al. Clinical Lung Cancer
- PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma
- (2021) Mohammad Jalili-Nik et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
- (2021) Jue Zhu et al. Journal of Ovarian Research
- PD-1/PD-L1-associated immunoarchitectural patterns stratify pancreatic cancer patients into prognostic/predictive subgroups
- (2021) Eva Karamitopoulou et al. Cancer Immunology Research
- STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
- (2021) Takashi Nakamura et al. Journal for ImmunoTherapy of Cancer
- Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer
- (2021) Xumin Zhou et al. Acta Pharmaceutica Sinica B
- Progress of MRI Radiomics in Hepatocellular Carcinoma
- (2021) Xue-Qin Gong et al. Frontiers in Oncology
- Rare primary pulmonary angiosarcoma with aberrant neuroendocrine differentiation
- (2021) Gianna N. DiGrazia et al. CLINICAL IMAGING
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
- (2021) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
- (2021) Luis G. Paz-Ares et al. Journal of Thoracic Oncology
- Autophagy-related signaling pathways in non-small cell lung cancer
- (2021) Jing Wang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer
- (2021) Joshua T. Eggold et al. MOLECULAR CANCER THERAPEUTICS
- Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1
- (2021) Ganji Purnachandra Nagaraju et al. SEMINARS IN CANCER BIOLOGY
- Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
- (2021) Christopher J. Pinard et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
- Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity
- (2021) Anukul T. Shenoy et al. Nature Communications
- Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
- (2021) Yunpeng Yang et al. Journal for ImmunoTherapy of Cancer
- PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis
- (2021) Long Chen et al. AMERICAN JOURNAL OF OTOLARYNGOLOGY
- Immune-resistant mechanisms in cancer immunotherapy
- (2020) Yutaka Kawakami et al. International Journal of Clinical Oncology
- Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
- (2020) Yuan Zhuang et al. OncoTargets and Therapy
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
- (2020) Manuela Tiako Meyo et al. Cancers
- Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
- (2020) Xiao-Song Li et al. BIOSCIENCE REPORTS
- Targeting glycosylated PD-1 induces potent anti-tumor immunity
- (2020) Linlin Sun et al. CANCER RESEARCH
- Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study
- (2020) Jianliang Yang et al. EUROPEAN JOURNAL OF CANCER
- Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer
- (2020) Ying Ma et al. GASTROENTEROLOGY
- The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
- (2020) Ina Nepstad et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Expression patterns of immune checkpoints in acute myeloid leukemia
- (2020) Cunte Chen et al. Journal of Hematology & Oncology
- The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
- (2020) Xueping Wang et al. Molecular Cancer
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms
- (2020) Alexander J Neuwelt et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
- (2020) Jayesh Desai et al. Journal for ImmunoTherapy of Cancer
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
- (2020) Vid Leko et al. CANCER CELL
- Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
- (2020) David H. Peng et al. Nature Communications
- High MHC-II expression in Epstein–Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation
- (2020) Farhad Ghasemi et al. Scientific Reports
- Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
- (2020) Zhengyi Wang et al. Cancer Medicine
- Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer
- (2020) Zhijie Wang et al. JAMA Network Open
- Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
- (2020) Jin-Yu Sun et al. Biomarker Research
- Cancer cell detection device for the diagnosis of bladder cancer from urine
- (2020) Melanie MacGregor et al. BIOSENSORS & BIOELECTRONICS
- Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas
- (2020) Devin Dersh et al. IMMUNITY
- Study on the Effect of Polymer Nano-Loaded Drug System on Bladder Cancer Perfusion
- (2020) Yao Lin et al. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
- Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
- (2020) Ranjan Pathak et al. Cancers
- Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
- (2020) Christie P. M. Verkleij et al. Cancers
- Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
- (2019) Ruohua Chen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
- (2019) Kathleen N Moore et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer
- (2019) Junlan Zhu et al. Cancers
- PD-1/PD-L1 Inhibitors in Cervical Cancer
- (2019) Yuncong Liu et al. Frontiers in Pharmacology
- Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer
- (2019) Sha Zhao et al. Cancer Immunology Research
- Autophagy inhibition enhances PD-L1 expression in gastric cancer
- (2019) Xiaojuan Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma
- (2019) Ai Kawamura et al. CANCER SCIENCE
- Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer
- (2019) Farhan S. Cyprian et al. Bosnian Journal of Basic Medical Sciences
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
- (2019) C G Kim et al. ANNALS OF ONCOLOGY
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer
- (2019) José Francisco Flores-Martín et al. ANNALS OF SURGICAL ONCOLOGY
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
- (2019) David J. Pinato et al. BRITISH JOURNAL OF CANCER
- A skewed distribution and increased PD‐1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia
- (2019) Jingying Huang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
- (2019) Dongkui Song et al. JOURNAL OF PATHOLOGY
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
- (2019) Michael A. Morse et al. ONCOLOGIST
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
- (2019) Wenfa Huang et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
- (2019) Stergios Boussios et al. Diagnostics
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
- (2019) Marian L. Burr et al. CANCER CELL
- A single-arm, multicenter, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma
- (2019) Yuqin Song et al. CLINICAL CANCER RESEARCH
- The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer
- (2019) Taher Abu Hejleh et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
- (2019) Yuqin Song et al. LEUKEMIA
- PD-1/PD-L1 Immune-Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects
- (2019) Alexis Rompré-Brodeur et al. MOLECULAR CANCER THERAPEUTICS
- Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells
- (2019) Mengyun Ke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia
- (2019) Kapil S. Meleveedu et al. LEUKEMIA & LYMPHOMA
- Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer
- (2019) Bi-Cheng Wang et al. MEDICINE
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
- (2019) Du-Bois Asante et al. CANCER LETTERS
- Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
- (2019) Johanna Veldman et al. CANCER TREATMENT REVIEWS
- Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma
- (2019) Mixue Xie et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
- (2018) ANTICANCER RESEARCH
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
- (2018) Masahiro Takeuchi et al. IMMUNOLOGY LETTERS
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint therapy in liver cancer
- (2018) Feng Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
- (2018) Rosemarie Tremblay-LeMay et al. Journal of Hematology & Oncology
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
- (2018) Varun Sasidharan Nair et al. Clinical Epigenetics
- Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
- (2018) Han Yao et al. Frontiers in Immunology
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
- (2018) Boyang Chang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
- (2018) A. Pawłowska et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
- (2018) Takashi Kawahara et al. BMC Urology
- Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Tomas Jelinek et al. Frontiers in Immunology
- Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Stefania Oliva et al. Frontiers in Immunology
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
- (2018) Yaxiong Zhang et al. Journal for ImmunoTherapy of Cancer
- PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
- (2018) Neda Yaghoubi et al. BIOMEDICINE & PHARMACOTHERAPY
- PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
- (2017) Paul Hofman EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma
- (2017) Chun-yu Huang et al. JOURNAL OF IMMUNOTHERAPY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
- (2017) Joseph P. Antonios et al. NEURO-ONCOLOGY
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms
- (2017) Manli Jiang et al. Expert Review of Hematology
- Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
- (2017) Zuqiang Liu et al. Nature Communications
- The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
- (2017) Nora Ness et al. Oncotarget
- Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade
- (2017) Jie Bai et al. Oncotarget
- Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
- (2017) Xinxin Zhu et al. Oncotarget
- Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
- (2017) Gerardo Botti et al. Journal of Cancer
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- PD-1/PD-L1 Pathway in Breast Cancer
- (2017) Florian Schütz et al. Oncology Research and Treatment
- Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
- (2017) Simran Sindhu et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
- (2016) Brant A. Inman et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
- (2016) Yaqi Li et al. Molecular Cancer
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
- (2016) David J. Pinato et al. OncoImmunology
- Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy
- (2015) M. V. Dhodapkar et al. BLOOD
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development
- (2010) E. Martin-Gayo et al. BLOOD
- PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
- (2008) C A Crane et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now